Maine Medicine Weekly Update - April 16, 2021  (Plain Text Version)

Return to Graphical Version


In this issue:
•  Maine Medical Association Statement on Johnson & Johnson COVID-19 Vaccine Pause
•  FDA Update & Statement on Johnson & Johnson COVID-19 Vaccine Pause Recommendation
•  Thrombotic Thrombocytopenia & J&J COVID Vaccine Response from the Manufacturer
•  Over 30 Percent of US Adults Fully Vaccinated, Maine Leads the Nation
•  Maine CDC COVID-19 Update for Clinicians with Stephen Sears, MD
•  Clinical Updates and Guidance Related to COVID-19
•  Medicare FFS Claims: 2% Payment Adjustment (Sequestration) Suspended Through December
•  MaineCare Updates: Upcoming Accountable Communities Public Webinar & Primary Care 2.0 Presentation Available Online
•  HealthCare Dive: Urgent Care Centers Draw Some ER Visits but Associated with Higher Spending Overall
•  Webinar for Medical Students April 22: So You Are Employed, Now What?
•  Next MMA Legislative Call Will Be Wednesday, April 21st
•  Maine Community Action Partnership is Working for a Successful Vaccine Roll Out for All
•  Maine Medical Association & ActionPPE Partner Again; This Time for FDA Approved Rapid Antigen Tests
•  A Message from Maine Responds: Volunteer Opportunity
•  Maine Legislature Week 14 Update
•  Maine Legislature Public Hearings, Work Sessions & New Bills
•  Upcoming Specialty Society Meetings
•  Maine CDC Physicians To Host Regular Clinician COVID Vaccine Info Sessions
•  "Prescribing to Reduce Opioid Overdose Risk: How to Impact the Epidemic Within the Pandemic"
•  NAMI Maine Workshops in May & June: Suicide Prevention & Management for Clinical Staff
•  AAP EQIPP Course: Immunizations - Strategies for Success (for RURAL Health Providers)
•  New Maine AAP Educational Webinar Series
•  Nurse Practitioner
•  Executive Director
•  Medical Director - ME License Required
•  Practice Administrator
•  Physician
•  Psychiatric Nurse Practitioner


FDA Update & Statement on Johnson & Johnson COVID-19 Vaccine Pause Recommendation

On Tuesday, the FDA and Centers for Disease Control and Prevention (CDC) issued a Statement regarding the Janssen (Johnson & Johnson) COVID-19 Vaccine.


On Tuesday, the FDA and Centers for Disease Control and Prevention (CDC) issued a Statement regarding the Janssen (Johnson & Johnson) COVID-19 Vaccine. Out of an abundance of caution, the FDA and CDC recommended a pause in the use of this vaccine while we review the data from six reported cases in the U.S. of a rare and severe type of blood clot in people who received the vaccine. This pause was recommended, in part, to ensure that the health care provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot. 

The FDA added three questions about the recommended pause in the use of this vaccine to the Janssen COVID-19 Frequently Asked Questions webpage and provided additional information and answered questions, Tuesday during an online media briefing. A recording of the call can be found on YouTube by clicking here.

American Medical Association President, Susan R. Bailey, MD, hosted a conversation with Peter Marks, MD, PhD, Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration (FDA) as part of its ongoing webinar series for physicians on COVID-19 vaccines. The most recent webinar focused on the Johnson & Johnson (Janssen) vaccine.  You can view the webinar at this link.

An Emergency ACIP meeting will be held to discuss the Johnson & Johnson COVID-19 vaccine next Friday, April 23, 2021, 11:00 a.m. to 5:00 p.m. ET. The webcast link of the meeting can be found here.